5-fluorouracil / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1043 Trials   1043 Trials   17947 News 


12345678910111213...328329»
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal, Cancer stem:  Modeling 5-FU-Induced Chemotherapy Selection of a Drug-Resistant Cancer Stem Cell Subpopulation. (Pubmed Central) -  Mar 27, 2024   
    (2) The expression of markers CD24, CD44, ALDH1, and ABCG2 was analyzed on the surface of CSCs in two cancer cell lines, MDA-MB-231 and HCT-116, after treatment with 5-fluorouracil (5-FU) using flow cytometry analysis...(4) Each individual GA prediction model achieved high accuracy in estimating the expression rate of CSC markers on cancer cells treated with 5-FU. Artificial intelligence can be used as a powerful tool for predicting drug resistance.
  • ||||||||||  5-fluorouracil / Generic mfg., ibuprofen / Generic mfg.
    Journal:  pNIPAm-Based pH and Thermoresponsive Copolymer Hydrogel for Hydrophobic and Hydrophilic Drug Delivery. (Pubmed Central) -  Mar 27, 2024   
    Moreover, the MTT assay and hemocompatibility analysis results proved that the pNIPAm-co-pGMA-Mela hydrogel system is biocompatible and hemocompatible, suggesting that that it could be used for drug delivery applications. The experimental results suggest that the proposed pNIPAm-co-pGMA-Mela hydrogel system is responsive to dual pH and temperature stimuli, and could be a promising drug carrier system for both hydrophilic and hydrophobic drug delivery applications.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., irinotecan / Generic mfg.
    Journal:  Vascularized tissue on mesh-assisted platform (VT-MAP): a novel approach for diverse organoid size culture and tailored cancer drug response analysis. (Pubmed Central) -  Mar 27, 2024   
    The PDX sample from a positive responder exhibited a significant reduction in cell viability across all organoid sizes when exposed to chemotherapeutic agents (5-FU, oxaliplatin, and irinotecan), as expected for cytotoxic drugs...Its capacity to handle various organoid sizes leads to results that more accurately reflect PDX models and differ markedly from traditional in vitro methods. The platform's distinct advantage lies in demonstrating how organoid size can critically influence drug response, revealing insights into cancer biology previously unattainable with conventional techniques.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Biomarker, Journal, Tumor mutational burden, Tumor microenvironment, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker:  Immune signature of small bowel adenocarcinoma and the role of tumor microenvironment. (Pubmed Central) -  Mar 26, 2024   
    Treatment involves platinum-based chemotherapy with a 5-fluorouracil combination, but the lack of effective chemotherapy contributes to a generally poor prognosis...The presence of PD-L1 and programmed cell death 1, along with tumor-infiltrating lymphocytes, plays a crucial role in the complex microenvironment of SBA and contributes to a more favorable prognosis, especially in the context of high MSI tumors. Stromal tumor-infiltrating lymphocytes are identified as independent prognostic indicators and the association between MSI status and a favorable prognosis, emphasizes the importance of evaluating the immune status of tumors for treatment decisions.
  • ||||||||||  elesclomol (STA-4783) / Madrigal Pharma
    Biomarker, Journal:  Validation of CDC45 as a novel biomarker for diagnosis and prognosis of gastric cancer. (Pubmed Central) -  Mar 26, 2024   
    Enrichment analysis revealed that CDC45 and its associated genes may play crucial roles in muscle biofunction, whereas GSEA demonstrated significant enrichment of gene sets pertaining to G protein-coupled receptor ligand binding and G alpha (i) signaling events. Our study elucidates that upregulation of CDC45 is intricately associated with immune cell infiltration and holds promising potential as a favorable prognostic marker and a novel diagnostic biomarker for GC.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Chemotherapy-induced pneumatosis intestinalis followed by hepatic portal venous gas. A case report. (Pubmed Central) -  Mar 25, 2024   
    We report here, a patient with liver metastases from colorectal cancer who developed PI followed by HPVG after treatment with 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6). Timely attention and management of gastrointestinal symptoms following chemotherapy are essential in the treatment of this type of patient.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Anthracycline-based hepatic arterial infusion chemotherapy achieved 17 (Pubmed Central) -  Mar 25, 2024   
    Depletion of CPNE7 attenuated the malignant proliferation of CRC cells and enhanced the chemosensitivity of CRC cells to 5-fluorouracil. A 46-year-old woman with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who had multiple LMs and bone metastases underwent seven lines of systemic therapy (paclitaxel/bevacizumab for 38
  • ||||||||||  5-fluorouracil / Generic mfg., cisplatin / Generic mfg.
    Journal:  RUVBL1 accelerates tongue squamous cell carcinoma by mediating CRaf/MEK/ERK pathway. (Pubmed Central) -  Mar 25, 2024   
    In conclusion, RUVBL1 contributes to the malignant biological behavior of TSCC via activating the CRAF/MEK/ERK pathway. This provides molecular mechanisms and perspectives for targeted therapy of the CRAF/MEK/ERK pathway.
  • ||||||||||  Cejemly (sugemalimab) / CStone Pharma
    Clinical, P3 data, Journal, Metastases:  First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. (Pubmed Central) -  Mar 25, 2024   
    P3
    All patients were randomized at 2:1 to receive either sugemalimab (an anti-PD-L1 antibody; 1,200?mg) or placebo every 3?weeks for up to 24?months, plus chemotherapy (cisplatin 80?mg?m-2 on day?1 plus 5-fluorouracil 800?mg?m-2?day-1 on days?1-4) every 3?weeks for up to six cycles. Sugemalimab plus chemotherapy significantly prolonged progression-free survival and overall survival in treatment-na
  • ||||||||||  5-fluorouracil / Generic mfg., docetaxel / Generic mfg.
    Trial completion date, Trial primary completion date:  Zhen Long: Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC (clinicaltrials.gov) -  Mar 25, 2024   
    P2,  N=24, Completed, 
    Here, we report a case of metachronous oligo-hepatic and peritoneal metastases in a patient who survived without recurrence for 3 Trial completion date: Jul 2023 --> Mar 2024 | Trial primary completion date: Oct 2022 --> Feb 2024
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Postoperative chemotherapy relative dose intensity and overall survival in patients with colon cancer. (Pubmed Central) -  Mar 23, 2024   
    In this study, the anti-proliferative and apoptotic effect of cannabinoid solution (THC:CBD at 1:6) at a dose of 1, 5, and 10 If chemotherapy RDI is considered a potential surrogate of overall survival, supportive care interventions that improve chemotherapy RDI might confer a potential clinical benefit in this population.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Journal, Surgery:  A Case of Conversion Surgery for Stage ? ATP-Producing Gastric Cancer with Distant Metastasis (Pubmed Central) -  Mar 22, 2024   
    After 2 courses of systemic chemotherapy FOLFOX/nivolumab, total gastrectomy, D2 node dissection, splenectomy pancreas tail resection, cholecystectomy, hepatic resection, partial transverse colon resection, partial jejunum resection, Roux-en-Y reconstruction...The pathological efficacy evaluation was Grade 1a in the primary tumor. The patient has been recurrence-free for 9 months since the initial diagnosis.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal, Metastases:  History and Perspective of Chemotherapy in Advanced Esophageal Cancer (Pubmed Central) -  Mar 22, 2024   
    trials, although no randomized controlled trials were conducted...In addition, the KEYNOTE-590 trial and the CheckMate 648 trial showed that pembrolizumab plus CF therapy was superior to CF, and nivolumab plus CF therapy and nivolumab plus ipilimumab were superior to CF in advanced esophageal carcinoma...Immune checkpoint inhibitors had prolonged survival, but the results are still unsatisfactory, and CF therapy combined with immune checkpoint inhibitors and novel agents is being investigated. This article reviews the history of chemotherapy in advanced or recurrent esophageal cancer and discusses future prospects.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Exploring Product Release from Yeast Cytosine Deaminase with Metadynamics. (Pubmed Central) -  Mar 22, 2024   
    After conversion of the prodrug into the toxic chemotherapeutic drug, 5-fluorouracil (5-FU), the slow product release from the enzyme limits the overall catalytic efficiency of the enzyme/prodrug system...Next, we use infrequent metadynamics to estimate the unbiased release rate from Kramers time-dependent rate theory and find a favorable comparison to experiment with a slower rate of product release for the 5-FU system. Our work demonstrates how adaptive sampling methods can be used to study the protein-ligand unbinding process for engineering enzyme/prodrug systems and gives insights into the molecular mechanism of product release for the yCD/5-FU system.
  • ||||||||||  evorpacept (ALX148) / ALX Oncology
    Trial completion date, Metastases:  A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) (clinicaltrials.gov) -  Mar 22, 2024   
    P1,  N=174, Active, not recruiting, 
    Our work demonstrates how adaptive sampling methods can be used to study the protein-ligand unbinding process for engineering enzyme/prodrug systems and gives insights into the molecular mechanism of product release for the yCD/5-FU system. Trial completion date: Feb 2024 --> Dec 2024
  • ||||||||||  Trial completion date, Trial primary completion date, Metastases:  SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) -  Mar 21, 2024   
    P3,  N=400, Recruiting, 
    Trial completion date: Sep 2029 --> Sep 2031 | Trial primary completion date: Jan 2029 --> Jan 2031 Trial completion date: Apr 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Dec 2026
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal:  Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications. (Pubmed Central) -  Mar 21, 2024   
    Bevacizumab is a humanized monoclonal anti-VEGF antibody often given in combination with fluorouracil-based chemotherapy as therapy for metastatic colorectal cancer (mCRC)...21 patients were identified who received bevacizumab and either apixaban or rivaroxaban for mCRC treatment...No patient experienced adverse thrombotic events. Patients with mCRC treated with bevacizumab and apixaban with no history of aspirin use within three years have a relatively low risk of bleeding that warrants treatment discontinuation.
  • ||||||||||  oxaliplatin / Generic mfg.
    Review, Journal, Metastases:  Role of Oxaliplatin in the Neoadjuvant Concurrent Chemoradiotherapy in Locally Advanced Rectal Cancer: a Review of Evidence. (Pubmed Central) -  Mar 21, 2024   
    We tried to define whether adding oxaliplatin to concurrent chemoradiation with excellent performance and high-risk features benefits some subpopulations. The available literature suggests that by adding oxaliplatin there are some benefits in enhancing response to neoadjuvant chemoradiotherapy, however, without any translated improvements in long-term outcomes including overall and disease-free survival.
  • ||||||||||  5-fluorouracil / Generic mfg., capecitabine / Generic mfg.
    Journal:  Fluoropyrimidine Toxicity: the Hidden Secrets of DPYD. (Pubmed Central) -  Mar 20, 2024   
    Additional post-translational DPD modifications, as well as DPD inhibition by other drugs, may explain a proportion of enzyme activity variability. Therefore, there is still a lot we can learn about the DPYD/DPD fluoropyrimidine-induced toxicity machinery.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Nanocomposite Hydrogels Based on Poly(vinyl alcohol) and Carbon Nanotubes for NIR-Light Triggered Drug Delivery. (Pubmed Central) -  Mar 18, 2024   
    Hydrophilic chemotherapeutic 5-fluorouracil (5-FU) and hydrophobic ibuprofen drugs were independently loaded into hydrogels, and the drug release profiles were obtained under passive and NIR-irradiation conditions...Appropriate concentrations of the nanocomposite hydrogel loaded with 5-FU produced cytotoxicity in cancer cells without affecting noncancerous cells. The overall properties of the MWCNT-f-containing hydrogel and its photothermal behavior make it an attractive material to promote the release of hydrophilic and hydrophobic drugs, depending on the treatment requirements.